by Raynovich Rod | Oct 5, 2016 | Biopharmaceuticals
Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft...
by Raynovich Rod | Sep 29, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… See Caution 9/29 Update-2…See Rayno Biobeat for updates after Trump Rally. For overweighting biotechs in a portfolio consider XBI instead of IBB to get mid and small cap exposure. ——– Rayno Portfolio Outperforms the Market...
by Raynovich Rod | Sep 26, 2016 | Biopharmaceuticals
Update-2… 9/29 Caution on Biotech-Major Sell-Off with IBB off 3.12% The market had a bad day today hit by Wells Fargo (WFC) Congressional hearings and paranoia about Deutsche Bank AG (DB). Unrelated to this news was a major sell-off in biotech stocks with...
by Raynovich Rod | Aug 31, 2016 | Biopharmaceuticals
Update-2… 945 am EDT…Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1…More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the...
by Raynovich Rod | Aug 28, 2016 | Biopharmaceuticals
Update-1… IBB Trying to hold the $280 line after media bashing of EpiPen Pricing- now they have a generic EpiPen for half the price! Biotech outflows are a concern (-$184M) Gilead Sciences (GILD) down 2.89% on new potential competition from GlaxoSmithK (GSK) HIV...
by Raynovich Rod | Aug 12, 2016 | Biopharmaceuticals
Large Cap Biopharmaceutical Valuation Models Can Biotech Growth Re-accelerate in Q4? We reviewed large cap biotech stocks on July 3 just after the BREXIT bottom but prior to Q2 earnings and on May 8 after Q1 earnings. Here is data that offer comparisons of the core...
by Raynovich Rod | Aug 10, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%, AMGN up 1.49% and CELG up 1.08%. Mid-caps also found bids: ALKS up...
by Raynovich Rod | Aug 4, 2016 | Biopharmaceuticals
8/5 After the Close… NASDAQ Up 1.06% The IBB inched up 0.38% to $297.29 while the more volatile XBI did better up 1.07%. Both are still down YTD and trail the QQQ which is up 4.39% YTD. Investors in biotech were not deterred by bad clinical news from...
by Raynovich Rod | Jul 27, 2016 | Biopharmaceuticals
Bullish Tone-Large Cap Biopharmaceutical Earnings Updates 8/5 Regeneron (REGN) shares fell another 2.4% to $423 despite a jump of 23% on Eylea sales to $832M compared to $655 M in the prior-year quarter. Higher expenses cut profitability as GAAP income was up only...
by Raynovich Rod | Jul 11, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still...